4180288/2025 - ALECTINIB 150MG CAPS - ANNUAL PROCESS

This tender, identified by reference 4180288/2025, is for the annual procurement of Alectinib 150mg capsules. Alectinib is a targeted therapy medication used primarily in the treatment of certain types of non-small cell lung cancer (NSCLC). This procurement process is an annual requirement, indicating a recurring need for this specific pharmaceutical product. The tender will likely specify the required quantities, quality standards (e.g., pharmaceutical grade, regulatory approvals), packaging, and delivery timelines. Potential suppliers must be authorized pharmaceutical manufacturers or distributors capable of meeting the stringent requirements of healthcare procurement. The objective is to ensure a consistent and reliable supply of Alectinib 150mg capsules for patient treatment throughout the year.

This is a supplies contract in the health and medical services, trade and industry and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 33,734.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.